このアイテムのアクセス数: 220

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
j.biomaterials.2021.121031.pdf15.78 MBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.authorIkeo, Satoshien
dc.contributor.authorYamamoto, Yukien
dc.contributor.authorIkeda, Kazuhiroen
dc.contributor.authorSone, Naoyukien
dc.contributor.authorKorogi, Yoheien
dc.contributor.authorTomiyama, Luciaen
dc.contributor.authorMatsumoto, Hisakoen
dc.contributor.authorHirai, Toyohiroen
dc.contributor.authorHagiwara, Masatoshien
dc.contributor.authorGotoh, Shimpeien
dc.contributor.alternative池尾, 聡ja
dc.contributor.alternative山本, 佑樹ja
dc.contributor.alternative池田, 和弘ja
dc.contributor.alternative曽根, 尚之ja
dc.contributor.alternative興梠, 陽平ja
dc.contributor.alternative松本, 久子ja
dc.contributor.alternative平井, 豊博ja
dc.contributor.alternative萩原, 正敏ja
dc.contributor.alternative後藤, 慎平ja
dc.date.accessioned2021-07-30T08:35:26Z-
dc.date.available2021-07-30T08:35:26Z-
dc.date.issued2021-09-
dc.identifier.urihttp://hdl.handle.net/2433/264609-
dc.descriptionヒトiPS細胞由来肺前駆細胞の拡大培養とマウス肺への移植・生着に成功 --肺再生医療の実現へ大きな一歩--. 京都大学プレスリリース. 2021-07-30.ja
dc.description.abstractLung transplantation is the only treatment available for end-stage lung diseases; however, donor shortage is a global issue. The use of human pluripotent stem cells (hPSCs) for organ regeneration is a promising approach. Nevertheless, methods for the expansion of isolated hPSC-derived lung progenitors (hLPs) for transplantation purposes have not yet been reported. Herein, we established an expansion system of hLPs based on their three-dimensional culture in core-shell hydrogel microfibers, that ensures the maintenance of their bipotency for differentiation into alveolar and airway epithelial cells including alveolar type II (AT2) cells. Further, we developed an efficient in vivo transplantation method using an endoscope-assisted transtracheal administration system; the successful engraftment and in vivo differentiation of hLPs into alveolar epithelial cells (incorporated into the alveoli) was observed. Importantly, expanded hLPs in the context of microfibers were successfully transplanted into the murine lungs, opening avenues for cell-based therapies of lung diseases. Therefore, our novel method has potential regenerative medicine applications; additionally, the high-quality hLPs and AT2 cells generated via the microfiber-based technology are valuable for drug discovery purposes.en
dc.language.isoeng-
dc.publisherElsevier BVen
dc.rights© 2021 The Author(s).en
dc.rightsPublished by Elsevier Ltd. This is an open access article under the Creative Commons Attribution license.en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/-
dc.subjectPluripotent stem cellsen
dc.subjectLung progenitorsen
dc.subjectCore-shell hydrogel microfibersen
dc.subjectThree-dimensional cell cultureen
dc.subjectXenotransplantationen
dc.subjectRegenerative medicineen
dc.titleCore-shell hydrogel microfiber-expanded pluripotent stem cell-derived lung progenitors applicable to lung reconstruction in vivoen
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleBiomaterialsen
dc.identifier.volume276-
dc.relation.doi10.1016/j.biomaterials.2021.121031-
dc.textversionpublisher-
dc.identifier.artnum121031-
dc.addressDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Drug Discovery for Lung Diseases, Graduate School of Medicine, Kyoto University; HiLung Inc.en
dc.addressCellFiber Co., Ltd,en
dc.addressDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Drug Discovery for Lung Diseases, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto University; Department of Drug Discovery for Lung Diseases, Graduate School of Medicine, Kyoto Universityen
dc.identifier.pmid34304138-
dc.relation.urlhttps://www.kyoto-u.ac.jp/ja/research-news/2021-07-30-1-
dcterms.accessRightsopen access-
datacite.awardNumber19J12072-
datacite.awardNumber17H05084-
datacite.awardNumber.urihttps://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-19J12072/-
datacite.awardNumber.urihttps://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-17H05084/-
dc.identifier.pissn0142-9612-
jpcoar.funderName日本学術振興会ja
jpcoar.funderName日本学術振興会ja
jpcoar.awardTitleヒトiPS細胞から肺胞上皮への分化制御機構の解明による肺胞再生とがん化モデル構築ja
jpcoar.awardTitle肺胞オルガノイド移植による組織再生治療に向けた安全性評価システムの確立ja
jpcoar.funderName.alternativeJapan Society for the Promotion of Science (JSPS)en
jpcoar.funderName.alternativeJapan Society for the Promotion of Science (JSPS)en
出現コレクション:学術雑誌掲載論文等

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons